Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.47 |
| ▸ | LIPC | P11150 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426120 | 0.95 | KMT2A (0.42) | LIPGLIPCKMT2ATAAR1USP1 | |
| SCHEMBL18426119 | 0.95 | KMT2A (0.42) | LIPGLIPCKMT2ATAAR1USP1 | |
| SCHEMBL4433970 | 0.86 | TAAR1 (0.46) | LIPGLIPCKMT2ATAAR1PDK2 | |
| SCHEMBL27037834 | 0.82 | PDK2 (0.40) | LIPGLIPCKMT2ATAAR1PDK2 | |
| SCHEMBL16333183 | 0.82 | PRMT5 (0.44) | LIPGLIPCKMT2A | |
| SCHEMBL16333181 | 0.82 | PRMT5 (0.44) | LIPGLIPCKMT2A | |
| SCHEMBL20362229 | 0.79 | LIPG (0.33) | LIPGLIPCTAAR1 | |
| SCHEMBL22835940 | 0.79 | LIPG (0.42) | LIPGLIPCKMT2ATAAR1PDK2 | |
| SCHEMBL22835620 | 0.79 | LIPG (0.42) | LIPGLIPCKMT2ATAAR1PDK2 | |
| SCHEMBL16414502 | 0.79 | LIPG (0.42) | LIPGLIPCKMT2ATAAR1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| EP-3013812-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | Nektar Therapeutics (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | LIPG 3427/4885LIPC 1653/4885KMT2A 3315/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | LIPG 3451/4885LIPC 1592/4885KMT2A 3260/4885 |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | LIPG 4216/4885LIPC 3119/4885KMT2A 2610/4885 |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRL1 | LIPG 4216/4885LIPC 3119/4885KMT2A 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.